Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.07% is 62% above its 5-year average of 3.13%, near the low end of its 5-year range (0.70%–25.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.43% below its 12-month average of 5.41%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.07%.
DEBT TO ASSETS RATIO
5.07%
DEBT TO ASSETS RATIO AVG TTM
5.41%
DEBT TO ASSETS RATIO AVG 3Y
3.57%
DEBT TO ASSETS RATIO AVG 5Y
3.13%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.43%
CURRENT VS 3Y AVG
+41.77%
CURRENT VS 5Y AVG
+61.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 571 covered companies
CURRENT VS SECTOR MEDIAN
+4965.39%
vs the sector median at left
Compass Therapeutics, Inc.
Market Cap
$173.51M
Debt to Assets Ratio
5.07%
TTM Avg
5.41%
3Y Avg
3.57%
5Y Avg
3.13%
Market Cap
$176.13M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.92M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$172.62M
Debt to Assets Ratio
0.22%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$181.64M
Debt to Assets Ratio
0.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$164.54M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$191.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $173.51M | 5.07% | 5.41% | 3.57% | 3.13% |
| Cue Biopharma, Inc. (CUE)vs › | $176.13M | 0.29% | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.92M | 0.00% | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.62M | 0.22% | N/A | N/A | N/A |
| MediWound Ltd. (MDWD)vs › | $172.45M | 0.13% | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $181.64M | 0.26% | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | 0.20% | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.61M | 0.00% | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | 0.00% | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.88M | 0.06% | N/A | N/A | N/A |
Debt/Assets
5.1%
Debt/Equity
0.06
Current Ratio
11.22
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.07% |
| 2026-03-31 | 4.77% |
| 2025-12-31 | 4.48% |
| 2025-09-30 | 4.27% |
| 2025-06-30 | 8.49% |
| 2025-03-31 | 4.85% |
| 2024-12-31 | 4.72% |
| 2024-09-30 | 4.61% |
| 2024-06-30 | 0.70% |
| 2024-03-31 | 0.88% |
| 2023-12-31 | 1.10% |
| 2023-09-30 | 1.20% |
| 2023-06-30 | 1.31% |
| 2023-03-31 | 1.41% |
| 2022-12-31 | 1.47% |
| 2022-09-30 | 2.52% |
| 2022-06-30 | 2.49% |
| 2022-03-31 | 2.57% |
| 2021-12-31 | 2.63% |
| 2021-09-30 | 23.34% |
| 2021-06-30 | 25.11% |
| 2021-03-31 | 25.68% |
| 2020-12-31 | 17.98% |
| 2020-09-30 | 18.44% |
| 2020-06-30 | 18.52% |
| 2020-03-31 | 70.50% |
| 2019-12-31 | 48.94% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
